Latest Biologicals News

TruScreen Group Limited reported a 19% revenue decline in FY2025 due to delayed rollouts in key emerging markets but anticipates a strong rebound with FY2026 sales forecast to exceed NZ$2.8 million.

Archer Materials has teamed up with UK-based Paragraf to fast-track development of its Biochip sensor for at-home chronic kidney disease testing, aiming to enhance accuracy and product readiness over six months.

Cynata Therapeutics confirms that the recent FDA orphan-drug exclusivity granted to Ryoncil® will not block approval of its CYP-001 therapy, highlighting key differences in drug composition and patient indications.

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.

Memphasys Limited has successfully trialed its RoXsta™ Mega Cell High-Throughput Assay, capable of processing 96 antioxidant tests in under an hour, promising a leap forward in rapid, cost-effective oxidative stress analysis.

Bio-Gene Technology Limited is progressing its development of two novel insecticidal compounds, Qcide and Flavocide, targeting major global markets with strong commercial validation and significant US Department of Defense funding.

Memphasys Limited has completed a pivotal Phase III trial confirming its Felix™ System as best-in-class for sperm separation, while advancing regulatory and commercial efforts in China and Brazil supported by fresh capital.

BPH Global Ltd has raised $609,000 through a targeted placement and made significant strides in its Indonesian seaweed venture, including binding offtake agreements and R&D breakthroughs on mineral extraction.

KNeoMedia advances toward ASX reinstatement after raising nearly $2.9 million and expanding its KneoScience platform across New York City schools, including a significant new high school content rollout.

Tissue Repair Limited reports progress in its Phase 3 clinical trials for TR987® despite enrollment delays caused by US regulatory disruptions, while TR Pro+® sales hit record highs and manufacturing scale-up advances.

Noxopharm Limited has successfully cleared key preclinical hurdles for its SOF-SKN™ lupus drug and expanded its Sofra™ platform collaborations, supported by fresh funding to propel upcoming clinical trials.

Battery Minerals Ltd has launched comprehensive geophysical and geochemical programs at its El Aguila Gold-Silver Project in Argentina, setting the stage for maiden drilling in Q3 2025 pending approvals.